Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Sponsor: Jin Li
Study ID: NCT06081595
Phase: PHASE2
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Relapsed Ovarian Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

Fluzoparib — DRUG
Fluzoparib 100mg bid
Apatinib — DRUG
Apatinib 375mg qd

Study Details

This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .

Key Dates

Start date: Oct 30, 2023
Status verified: Oct 2023
Primary completion: Dec 30, 2024
Completion: Dec 30, 2026

Study Design

Enrollment: 54 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Fluzoparib+Apatinib combination

Primary Outcome Measure

Progression Free Survival(PFS) [ Time Frame: Up to 2 years ]